ImpediMed

09/02/2026

The SOZO® Digital Health Platform is now FDA-cleared for sarcopenia risk assessment, the only FDA-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of sarcopenia risk.

In cancer care, muscle loss can shape how well a patient tolerates treatment and recovers. Now clinicians can assess sarcopenia risk from the same rapid SOZO scan already in their oncology workflow.

"Flagging the risk early, from a routine scan, means we can act while it's reversible," said Jay K. Harness, MD, FACS, Past-President of the American Society of Breast Surgeons.

🔗 Read the announcement: https://ow.ly/M9eY50ZIr3K

08/31/2026

By the time lymphedema is visible, it's harder to manage.

That's why surveillance matters. Measuring subclinical fluid changes lets care teams act in the window before symptoms set in, when intervention is most effective, and lymphedema is reversible.

The SOZO® Digital Health Platform with L-Dex® supports early detection as part of structured lymphedema surveillance, in line with NCCN guidelines and NAPBC standards.

🔗 Learn more: https://ow.ly/ABKA50ZHqUX

08/28/2026

Survivorship care is expanding to include the whole patient: nutrition, physical activity, weight, and the lifestyle changes that support long-term health.

For survivors managing weight, including those on GLP-1 therapy, preserving muscle matters. Physical activity and muscle maintenance are increasingly part of the survivorship conversation.

BodyComp™ monitoring gives care teams an objective way to track how a survivor is responding to these interventions over time, not just what the scale shows. That visibility can support engagement, compliance, and some reassurance along the way.

🔗 Learn more: https://ow.ly/rKhF50ZGhzU

08/26/2026

Return-to-play decisions are only as strong as the data behind them.

Next week's webinar covers the clinical outputs bioimpedance spectroscopy (BIS) brings to sports medicine: intracellular and extracellular fluid (ICF/ECF), phase angle, and skeletal muscle mass, and what each one signals about an athlete's hydration, cellular health, and readiness.

📅 Wednesday, September 2, 6pm ET

Featured faculty: Jordan R. Moon, PhD, CSCS; Dawn Nasta; and Chad Sirratt, AS, MAT, NSCA.

Register here: https://impedimed.zoom.us/webinar/register/WN_VpwOvUB2RwKnGnU_7Bp7Dg

08/24/2026

We’re pleased to welcome Erik Johnson to ImpediMed as Head of Sales.

Erik brings over 15 years of medical technology sales leadership to this role. Erik has held progressive sales leadership roles over the past 12 years at Hologic, delivering consistent revenue growth across Breast & Skeletal Health, Medical Aesthetics, and Breast Surgery.

Erik’s track record in high growth sales performance and leadership development is key to ImpediMed’s focus on commercial ex*****on and expansion of the SOZO® Digital Health Platform across the cancer survivorship care continuum.

Welcome to the team Erik!

08/20/2026

Two athletes can carry the same body weight and be in very different states of recovery. What the scale shows and what's happening at the tissue level are not the same thing.

On Wednesday, September 2nd at 6pm ET, join a free webinar on how bioimpedance spectroscopy (BIS) is applied in sports medicine: establishing athlete baselines, reading fluid balance and phase angle, and using that data to inform recovery and return-to-play decisions.

Featured faculty: Jordan R. Moon, PhD, CSCS, Dawn Nasta, and Chad Sirratt, AS, MAT, NSCA.

Register Now: https://ow.ly/FTis50ZBy9I

08/18/2026

Big news for cancer care: SOZO® has received FDA clearance for sarcopenia risk assessment.

Sarcopenia — the loss of muscle mass and strength — affects roughly 1 in 3 breast cancer patients during chemo, yet it often goes undetected because traditional tools (DXA, CT) aren't built for frequent monitoring.

Now clinicians can assess sarcopenia risk from the same 30-second SOZO scan already used for lymphedema and body composition monitoring — no extra appointment, no added radiation.

"Sarcopenia is one of the most consequential and most overlooked risks in cancer care," says Erik Anderson, CEO of ImpediMed. "This clearance gives clinicians a practical way to see what's happening inside the body, from a scan already built into their workflow."

Muscle loss is modifiable — catching it early means patients have a better shot at finishing treatment strong and recovering well. SOZO supports that patient journey from diagnosis, through treatment and survivorship.

🔗 View the Release: https://ow.ly/JV9v50ZB0B0

SOZO® is now the only FDA-cleared BIS solution for sarcopenia risk assessment—flagging muscle loss early from a rapid routine scan in cancer care.

08/11/2026

Up to 20% of weight loss on GLP-1 therapy can be muscle, not fat.

For patients, that difference matters. Losing muscle alongside fat can affect strength, resilience, and how well treatment is tolerated over time.

The scale can't tell you which kind of weight is coming off. BodyComp™ monitoring can, measuring fat and lean mass so care teams can step in early if muscle loss becomes a concern.

🔗 Learn more: https://ow.ly/MXrz50Zy8Tw

08/06/2026

For many cancer survivors, the fear that it could come back doesn't fully fade. Up to 60% report a fear of recurrence, and that is reshaping survivorship care toward the whole patient: quality of life, and the lifestyle factors that support long-term health.

BodyComp™ monitoring gives care teams an objective way to see how a survivor is responding to nutrition, exercise, and other interventions over time, including whether muscle is being preserved. That visibility helps keep patients engaged in their own care and gives clinicians a clearer picture than the scale alone.

🔗 Learn more about survivorship care beyond treatment: https://ow.ly/KpLP50ZwGBU

08/04/2026

In sports performance, what the scale shows matters far less than what that weight is made of.

This weekend, Chiron Sports Performance opened in Bloomfield Hills, MI, with a physician-led, data-driven approach to athlete care. As part of their assessments, the team is using the SOZO® Digital Health Platform to measure fluid, fat, and skeletal muscle mass in a single 30-second scan. With SOZO Pro on site, they have objective data to inform how athletes train and recover.

Our Sr. Training and Education Specialist, Maureen McBeth, was there for the grand opening.

Congratulations to the Chiron team!